Etripamil: How JPA Health Amplified Pivotal Cardiology Trial Data at AHA
JPA Health helped bring attention to pivotal Phase 3 clinical data for Milestone Therapeutics’ investigational therapy etripamil, being studied to treat paroxysmal supraventricular tachycardia (PSVT), an abnormality in the electrical system of the heart. There is no cure for this condition.
The Impact
5
Media
Interviews
20
Original
News
Articles
100M
Potential
Audience
Reach
The Challenge
The American Heart Association (AHA) Annual Scientific Session is a crowded and busy medical congress. JPA Health was tasked with securing a steady drumbeat of media coverage that would raise awareness of etripamil’s positive Phase 3 data ahead of Milestone’s submission to the U.S. Food and Drug Administration.
Our Approach
JPA Health crafted a targeted embargoed media outreach strategy that would amplify top-line pivotal data to key audiences. This approach allowed influential reporters the opportunity to review the trial’s findings ahead of AHA and allowed them adequate time to speak directly with Milestone spokespeople.
The Solution
Ahead of AHA, we conducted embargoed outreach to key reporters with an offer to join a weekend virtual roundtable to discuss the data prior to its release. During the roundtable, Milestone gave a brief presentation on the data followed by a Q&A with reporters. JPA Health also implemented an ongoing, non-embargoed media strategy to an extended list of outlets to prolong coverage past release day.
This strategy led to positive coverage in opinion-shaping outlets including STAT News, FierceBiotech, Endpoints News, BioSpace, Kaiser Health News, Medscape and more.
